Stem cells for vascular tissue engineering; signaling pathways in cell-cell adhesion and wound healing; lentiviral vectors and lentiviral microarrays for high-throughput gene expression analysis and gene discovery
908 Furnas Hall
Buffalo NY, 14260
Phone: (716) 645-1202
Fax: (716) 645-3822
Stelios Andreadis focuses on tissue engineering and stem cell biology. His pioneering work encompasses a rare blend of both breadth and depth in tissue engineering and regenerative medicine, due to his unique insight into both molecular scale mechanisms and engineering fundamentals, and how they influence key macroscopic, functional tissue engineering outcomes in the skin, glands, smooth muscle, blood vessels and more recently neural crest lineages. His research has led to an improved source of stem cells, improved understanding of vascular aging and how to reverse it, improved understanding of molecular events for improving tissue engineered products, and real world products to replace arteries in patients.
His research group’s contributions include engineered tools for systems biology analysis of stem cells, biological discovery, drug delivery and biomaterials, and bioengineered products for translational medicine. For example, they have engineered gene arrays for understanding the systems level dynamics of gene expression in live stem cells under various microenvironmental conditions to address gaps in our understanding of major biological processes, like stem cell differentiation. In the areas of drug delivery and biomaterials, his research group developed novel techniques to improve tissue engineering outcomes like wound healing.
In the area of stem cell bioengineering, his group has identified new molecular pathways in a key cellular process cell-cell adhesion, and a key role for these pathways in biomechanical signaling and stem cell differentiation.
Notably, his research group discovered that the pluripotency factor, Nanog reversed aging of stem cells yielding functional stem cells and may lead to more functional and rejuvenated tissues in patients.
In the area of stem cell reprogramming, his group recently reported the novel finding that skin stem cells can be reprogrammed into neural crest stem cells and their derivatives, including neurons, Schwann cells and melanocytes. This reprogramming strategy does not require genetic modification thereby providing an abundant, highly accessible and autologous source of stem cells for potential treatment devastating diseases of the peripheral and central nervous system, for which cell sourcing remains a severe impediment.
Finally, his group has pioneered cell-free tissue engineered vascular arterial grafts which are transplantable and functional. These pioneering studies have led to a start-up (Angiograft, LLC) bring these cell-free vascular grafts to clinical trials and for wide applications for vascular diseases of the heart, brain, and extremities.
He received his MS (Applied Mathematics) and PhD degree in Chemical Engineering from the University of Michigan in the dynamics of retroviral gene transfer for gene therapy. He then pursued postdoctoral training at the Center for Engineering in Medicine at Harvard Medical School, where he trained in the areas of gene therapy, tissue engineering and regenerative medicine. Currently he serves as Professor and Chair of Chemical and Biological Engineering, Professor of Biomedical Engineering and is a member of the UB Center of Excellence in Bioinformatics and Life Sciences. He is also the Director of the Stem Cells in Regenerative Medicine (SCiRM) Training Program that was recently funded by NYSTEM to train students in stem cell biology and bioengineering and applications of stem cells in regenerative medicine.
Professor Andreadis’ research has received continuous funding since 1999 from NIH, NSF, NYSTEM and private foundations (Whitaker, Oishei), totaling more than $18 million. Among his numerous accolades, Professor Andreadis is the recipient the Whitaker Foundation Young Investigator Award (1999), the NSF CAREER Award (2000), the Exceptional Scholar Young Investigator Award (UB, 2003), Exceptional Scholar: Sustained Achievement Award (UB, 2009) and the SUNY Chancellor’s Award for Excellence in Scholarship (2014). He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE, 2009) and of the Biomedical Engineering Society (BMES, 2016). With his laboratory colleagues he has published more than 135 peer-reviewed publications and conference proceedings and delivered more than 70 invited seminars. He has advised 24 Ph.D. students, 16 M.S. students, 4 post-doctoral research fellows and more than 40 undergraduate researchers. His former Ph.D. students hold tenure-track academic positions (U of South Florida, UB, IIT Kanpur in India, The Capital University of Medical Sciences in Beijing, China); post-doctoral positions at top Universities (Harvard, Stanford, Johns Hopkins, Univ. of Pennsylvania); or research and leadership positions in leading pharmaceutical/biotechnology companies (Shire Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Life Technologies, MedImmune and others).